Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Michael Tuttle

Showing results (111-120 of 320) with videos related to

Pageof 32
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2011
The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi power facility: technical, radiologic, and response perspectivesLawrence T Dauer, Pat Zanzonico, R Michael Tuttle, et al.
Thyroid : Official Journal of the American Thyroid Association|July 26, 2012
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scansMona M Sabra, Ravinder K Grewal, Hernan Tala, et al.
Endocrine|November 2, 2020
Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient countryFriederike Eilsberger, R Michael Tuttle, Damiano Librizzi, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2002
Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?Richard J Robbins, Jajin Thomas Chon, Martin Fleisher, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 8, 2020
Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the USBenjamin R Roman, Piyush Gupta, R Michael Tuttle, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2004
Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adultsAneeta Patel, Thomas Pluim, Amy Helms, et al.
Cancer|March 25, 2011
Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapyN Gopalakrishna Iyer, Luc G T Morris, R Michael Tuttle, et al.
Annals of Surgical Oncology|July 2, 2009
Micromedullary thyroid cancer: how micro is truly micro?Venu G Pillarisetty, Steven C Katz, Ronald A Ghossein, et al.
Thyroid : Official Journal of the American Thyroid Association|February 5, 2009
Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern)Michael Rivera, R Michael Tuttle, Snehal Patel, et al.
Thyroid : Official Journal of the American Thyroid Association|February 16, 2010
Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survivalLuc G T Morris, Ashok R Shaha, R Michael Tuttle, et al.
Pageof 32

Showing results (111-120 of 320) with videos related to

Sort By:
Pageof 32
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2011
The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi power facility: technical, radiologic, and response perspectivesLawrence T Dauer, Pat Zanzonico, R Michael Tuttle, et al.
Thyroid : Official Journal of the American Thyroid Association|July 26, 2012
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scansMona M Sabra, Ravinder K Grewal, Hernan Tala, et al.
Endocrine|November 2, 2020
Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient countryFriederike Eilsberger, R Michael Tuttle, Damiano Librizzi, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2002
Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?Richard J Robbins, Jajin Thomas Chon, Martin Fleisher, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 8, 2020
Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the USBenjamin R Roman, Piyush Gupta, R Michael Tuttle, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2004
Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adultsAneeta Patel, Thomas Pluim, Amy Helms, et al.
Cancer|March 25, 2011
Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapyN Gopalakrishna Iyer, Luc G T Morris, R Michael Tuttle, et al.
Annals of Surgical Oncology|July 2, 2009
Micromedullary thyroid cancer: how micro is truly micro?Venu G Pillarisetty, Steven C Katz, Ronald A Ghossein, et al.
Thyroid : Official Journal of the American Thyroid Association|February 5, 2009
Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern)Michael Rivera, R Michael Tuttle, Snehal Patel, et al.
Thyroid : Official Journal of the American Thyroid Association|February 16, 2010
Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survivalLuc G T Morris, Ashok R Shaha, R Michael Tuttle, et al.
Pageof 32